Episode Details

Johnson & Johnson is poised to close a 12-year legal saga with a $5.5 billion settlement over talc-linked ovarian cancer claims, after a previous $9 billion bid was rejected by a bankruptcy judge. The deal, contingent on remaining claimants signing on, marks a major step toward resolving decades of litigation—including mesothelioma cases and supplier disputes—and includes a $3 billion initial payment in 2027, with the rest due in 2028, designed to ease financial strain while bringing long-awaited closure to a complex and high-stakes legal battle.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/5372fc179f93385f